Open Access iconOpen Access

ARTICLE

crossmark

IGF2BP3-induced activation of EIF5B contributes to progression of hepatocellular carcinoma cells

XIAOYIN LI1,#, QIAN WANG2,#, HONGFENG LIANG3,#, SHISHENG CHEN4,#, HAIWEN CHEN1,#, YAOYONG LU1,*, CHANGFU YANG1,*

1 Department of Oncology (Section 3), Gaozhou People’s Hospital, Gaozhou, China
2 South China Research Center for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, China
3 The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangzhou, China
4 Nanfang Hospital Taihe Branch, Guangzhou, China

* Corresponding Authors: YAOYONG LU. Email: email; CHANGFU YANG. Email: email

Oncology Research 2022, 30(2), 77-87. https://doi.org/10.32604/or.2022.026511

Abstract

In this study, we investigated the functional role of eukaryotic initiation factor 5B (EIF5B) in hepatocellular carcinoma (HCC) and the underlying mechanisms. Bioinformatics analysis demonstrated that the EIF5B transcript and protein levels as well as the EIF5Bcopy number were significantly higher in the HCC tissues compared with the non-cancerous liver tissues. Down-regulation of EIF5B significantly decreased proliferation and invasiveness of the HCC cells. Furthermore, EIF5B knockdown suppressed epithelial-mesenchymal transition (EMT) and the cancer stem cell (CSC) phenotype. Down-regulation of EIF5B also increased the sensitivity of HCC cells to 5-fluorouracil (5-FU). In the HCC cells, activation of the NF-kappa B signaling pathway and IkB phosphorylation was significantly reduced by EIF5B silencing. IGF2BP3 increased the stability of the EIF5B mRNA in an m6A-dependent manner. Our data suggested that EIF5B is a promising prognostic biomarker and therapeutic target in HCC.

Keywords


Supplementary Material

Supplementary Material File

Cite This Article

LI, X., WANG, Q., LIANG, H., CHEN, S., CHEN, H. et al. (2022). IGF2BP3-induced activation of EIF5B contributes to progression of hepatocellular carcinoma cells. Oncology Research, 30(2), 77–87.



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 1030

    View

  • 566

    Download

  • 0

    Like

Share Link